Population | Adults (aged (≥18 years) with episodic or chronic migraine with or without aura (where specified, International Headache Society diagnostic criteria, Headache Classification Committee of the International Headache Society, 2013 [34]) |
Intervention/comparators | Lasmiditan (50 mg, 100 mg, 200 mg) Rimegepant (75 mg) Ubrogepant (25 mg, 50 mg, 100 mg) |
Outcomes | • Pain freedom at 2 hours (pain reduced from moderate or severe to none without use of rescue medication within 2 hours) • Pain relief at 2 hours (pain reduced from moderate or severe to none or mild without use of rescue medication within 2 hours) • Pain relief at 1 hour (pain reduced from moderate or severe to none or mild without use of rescue medication within 1 hour) • MBS freedom at 2 hours (freedom from the MBS, as identified by the patient, from the associated symptoms of nausea, phonophobia and photophobia) • Sustained pain freedom over 24 hours (pain freedom at 2 hours, sustained for 24 hours, without the use of rescue medication or a second dose of study medication) • Discontinuation due to AEs |
Study design | Randomised controlled trials |